These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 15028478)

  • 1. Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer.
    Shirakawa T; Gotoh A; Zhang Z; Kao C; Chung LW; Gardner TA
    Urology; 2004 Mar; 63(3):613-8. PubMed ID: 15028478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
    Gotoh A; Ko SC; Shirakawa T; Cheon J; Kao C; Miyamoto T; Gardner TA; Ho LJ; Cleutjens CB; Trapman J; Graham FL; Chung LW
    J Urol; 1998 Jul; 160(1):220-9. PubMed ID: 9628654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
    Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
    Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model.
    Cheon J; Ko SC; Gardner TA; Shirakawa T; Gotoh A; Kao C; Chung LW
    Cancer Gene Ther; 1997; 4(6):359-65. PubMed ID: 9408606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
    Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM
    Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters.
    Majumdar AS; Hughes DE; Lichtsteiner SP; Wang Z; Lebkowski JS; Vasserot AP
    Gene Ther; 2001 Apr; 8(7):568-78. PubMed ID: 11319624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models.
    Ko SC; Cheon J; Kao C; Gotoh A; Shirakawa T; Sikes RA; Karsenty G; Chung LW
    Cancer Res; 1996 Oct; 56(20):4614-9. PubMed ID: 8840973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adenovirus-mediated double suicide gene selectively kills breast cancer MCF-7 cells in vitro].
    Kong H; Huang ZH; Li Q; Yang LC; Yu JL; Li Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jun; 28(6):907-10. PubMed ID: 18583225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
    Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
    Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human prostate cancer progression models and therapeutic intervention.
    Chung LW; Kao C; Sikes RA; Zhau HE
    Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy.
    Hayashi K; Lee JB; Maitani Y; Toyooka N; Nemoto H; Hayashi T
    J Gene Med; 2006 Aug; 8(8):1056-67. PubMed ID: 16779868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cloning and analysis of human UroplakinII promoter and its application for gene therapy in bladder cancer.
    Zhu HJ; Zhang ZQ; Zeng XF; Wei SS; Zhang ZW; Guo YL
    Cancer Gene Ther; 2004 Apr; 11(4):263-72. PubMed ID: 14963492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy.
    Shirakawa T; Ko SC; Gardner TA; Cheon J; Miyamoto T; Gotoh A; Chung LW; Kao C
    Cancer Gene Ther; 1998; 5(5):274-80. PubMed ID: 9824046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat-directed suicide gene therapy mediated by heat shock protein promoter for gastric cancer.
    Isomoto H; Ohtsuru A; Braiden V; Iwamatsu M; Miki F; Kawashita Y; Mizuta Y; Kaneda Y; Kohno S; Yamashita S
    Oncol Rep; 2006 Mar; 15(3):629-35. PubMed ID: 16465423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
    Song Y; Shen K; Yu JR
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional targeting of virus-mediated gene transfer by the human hexokinase II promoter.
    Määttä AM; Korja S; Venhoranta H; Hakkarainen T; Pirinen E; Heikkinen S; Pellinen R; Mäkinen K; Wahlfors J
    Int J Mol Med; 2006 Nov; 18(5):901-8. PubMed ID: 17016620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia.
    Nelson DW; Cao H; Zhu Y; Sunar-Reeder B; Choi CY; Faix JD; Brown JM; Koong AC; Giaccia AJ; Le QT
    Cancer Res; 2005 Jul; 65(14):6151-8. PubMed ID: 16024616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tandemly repeated thyroglobulin core promoter has potential to enhance efficacy for tissue-specific gene therapy for thyroid carcinomas.
    Takeda T; Yamazaki M; Minemura K; Imai Y; Inaba H; Suzuki S; Miyamoto T; Ichikawa K; Kakizawa T; Mori J; DeGroot LJ; Hashizume K
    Cancer Gene Ther; 2002 Oct; 9(10):864-74. PubMed ID: 12224028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct.
    Hakkarainen T; Wahlfors T; Meriläinen O; Loimas S; Hemminki A; Wahlfors J
    J Gene Med; 2005 Jul; 7(7):898-907. PubMed ID: 15759279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.